Abstract Background: The differentiation of benign mesothelial cells from malignant tumor cells, primary, or metastatic, in serous effusions based on cytomorphologic features alone can be problematic. Purpose: This study was conducted to evaluate the utility of p53 and ki67 immunocytochemical markers in differentiating benign from malignant tumor cells in serous effusions. Patients and methods: Archival Papanicolaou-stained smears of 91 pleural and peritoneal effusions were retrieved from Cytology Unit, Pathology Department, NCI, Cairo University between 2008 and 2010. Forty-one cases were positive for malignant cells and 50 cases were benign based on cytomorphologic features. Cases having doubt were excluded from the study. The slides were destained and subjected to immunocytochemical staining for p53 and ki67. Histologic sections of colonic carcinoma and tonsillar tissue were used as positive control for p53 and ki67, respectively. Smears having >5% positively stained nuclei for p53 were taken as positive and labeling index P10% of ki67 was considered positive. Frequencies of the individual immunocytochemical stains; p53 and ki67, in benign and malignant effusion as well as the combination of both stains were calculated. Results: p53 immunostaining showed nuclear positivity in 31 out of 41 malignant effusions (75.6%) and in 3 out of 50 benign effusions (6%), p < 0.005. p53 had 75.6% sensitivity, 94% specificity, 91.2% PPV, and 82.5% NPV. ki67 immunostaining was positive in 30 out of 41 malignant effusions (73.2%) and in 17 out of 50 benign effusions (34%), p < 0.05. ki67 had 73.2% sensitivity, 66% specificity, 63.8% PPV, and 75% NPV. Cases were then analyzed for combined immunoprofile of p53 and ki67. Among the 24 cases that coexpressed both antigens, 22 cases (91.7%) were malignant. Thirty two out of 34 cases (94.1%) that showed negative results for both antigens were benign. For the cases that showed p53 immunostaining only, 9 out of 10 cases (90%) were malignant. Fifteen out of 23 cases (65.2%) that showed ki67 immunostaining were benign. Conclusion: Benign and malignant effusions showed significantly different staining pattern for p53 and ki67. When used individually, p53 immunostaining can truly diagnose 75.6% and 94% of the malignant and benign cases, respectively. ki67 immunostaining can correctly identify 73.2% and 66% of the malignant and benign cases, respectively. When used in combination, 91.7% of p53 and ki67 positive cases were malignant while 94% of p53 and ki67 negative cases were benign. Hence they could be used when the cytomorphology fails to provide a definitive diagnosis.
Introduction
Identification of malignant, metastatic, or primary malignant mesothelial cells in serous effusions using cytomorphology alone is a well known diagnostic problem and is challenging to cytopathologists [1] . Reactive mesothelial cells in response to many benign conditions may be difficult to distinguish from malignant cells particularly when the former cells occur in clumps and show various degree of cytologic atypia [2] . The cytologic features commonly used to identify malignancy, including nuclear pleomorphism, macronucleoli, large cellular aggregates, papillarylike tissue fragment, and cell in cell engulfment are helpful features but have limited use in effusion because they may also be present in florid reactive mesothelial hyperplasia [3] .
Thus, the availability of techniques that would enhance the diagnostic accuracy of routine cytological methods could be of great clinical value. Ancillary techniques such as electron microscope, flow cytometry, and morphometry have been used to solve the ambiguity in cytological differential diagnosis. However, these are of limited use owing to the high cost, availability at only few specialized centers, requirement of highly skilled personnel, and low sensitivity and specificity [4] . The application of immunocytochemical technique to serous effusion is more sensitive and specific than other methods and easy availability of reagents for use in most of the laboratories make it a good choice [5] .
Some studies have suggested that the protein product of tumor suppressor gene p53 has been found to be overexpressed more frequently in malignant cells than reactive mesothelial proliferation [6, 7] . The proliferation cell markers have been also used to aid the diagnosis of various benign and malignant tumors and to predict patient's survival for a variety of tumors. The proliferation marker ki67 may be useful in separating mesothelial proliferation from malignant cells [8, 9] .
p53 is a 53-kDa nuclear protein product of tumor suppressor gene p53 that is located on the short arm of chromosome 17. It is involved in several cellular functions including transcription, regulation of the cell cycle, DNA repair, and induction of apoptosis to preserve the genetic stability. Deletions or mutations in p53 gene are common in human malignancies (60%) leading to tumor growth [10] . The resultant mutated p53 gene product has a longer half life than the normal protein and increased stability of aberrant p53 proteins renders them more readily detectable by immunostaining means. Thus the highly increased level of mutated gene product in malignant cells differentiates them from benign cells [11] . ki67 antigen is a cell proliferation-related non-histone nuclear protein that can be labeled with monoclonal antibody MIB-1. The antigen is expressed in the nuclei of cells in active phases of cell cycle (G1, S, G2, M) except resting phase (G0). ki67 can be used to assess the growth fraction (the number of cells in cell cycle) of normal, reactive, and neoplastic tissue [12] . The percentage of ki67 positive cells (labeling index) is usually low in benign lesions but increases in malignant tumors. High ki67 index is an excellent marker to recognize rapidly proliferating cell that would indicate malignancy and might affect recurrence rate and survival [13] .
The aim of the current study is to evaluate the utility of p53 and ki67 immunocytochemical markers in differentiating benign mesothelial cell proliferation from malignant tumor cells, primary, or metastatic, in serous effusions.
Patients and methods
Archival Papanicolaou-stained smears of 91 pleural and peritoneal effusions were retrieved from the Cytology Unit, Pathology Department, National Cancer Institute, Cairo University between 2008 and 2010. Forty-one cases were positive for malignant cells and 50 cases contained benign reactive mesothelial hyperplasia. No cases having doubt were included in the study. Effusions were labeled as benign or malignant on the basis of cytological examination using the standard cytomorphologic features for cytologic diagnosis of serous effusion [14] .
Two cases of malignant effusions had confirmatory histologic diagnosis of malignant mesothelioma. The remaining malignant effusions were confirmed with the previous and/or the current clinical and radiological findings reviewed from the hospital records that showed: The slides were destained using the technique described by Miller and Kubier [15] . The destained slides were subjected to immunocytochemical staining for p53 and ki67 according to the streptavidin-biotin-peroxidase technique using the mouse monoclonal antibody Thermo Scientific Lab Vision, anti-p53 Ab-6, clone DO-1 (dilution 1:30) and rabbit monoclonal antibody Thermo Scientific Lab Vision, anti-ki67, clone SP6 (dilution 1:100).
A positive control slide was run with each staining set to ensure that all reagents were working properly. Histologic sections of colonic carcinoma and tonsillar tissue were used as positive control for p53 and ki67, respectively; and a negative control was used by substituting phosphate buffered saline (PBS) for the primary antibody to evaluate non-specific staining and better interpretation of specific staining. All controls yielded appropriate results. Only the nuclear immunoreactivity for both p53 and ki67 was considered specific. Cytoplasmic and membranous staining was considered non-specific. All slides were immunocytochemically evaluated without any information of clinical, cytopathological, or radiological data.
The result of p53 immunocytochemical stain was scored as: negative if there was no nuclear staining in the examined epithelioid cells, focal positive if there was nuclear staining in 65% of cells, and positive if there was nuclear staining in >5% of cells. For ki67, the percentage of positively stained nuclei out of the total epithelioid cell counted was estimated (the labeling index) and categorized as: negative if no nuclear staining in the examined epithelioid cells, low if there was nuclear staining in 610% of cells, moderate if there was nuclear staining in 10-40% of cells, and high if there was nuclear staining in >40% of cells.
For all immunocytochemical stains, the results were independently scored by the two cytopathologists and any discrepant cases were reviewed at a double-headed microscope to achieve consensus. Statistical analysis of the individual immunocytochemical stains; p53 and ki67, in benign and malignant effusions as well as the combination of both stains were calculated using statistical package for social science (SPSS), version 12.
Results
The 41 cases of malignant effusion consisted of 26 females (63.4%) and 15 males (36.6%) with an age range of 44-76 years (mean age was 53.9 years and median age was 56 years). The 50 cases of benign effusion consisted of 28 males (56%) and 22 females (44%) with an age range 31-62 years (mean age was 45.2 years and median age was 49 years).
Twenty-nine cases of the 50 benign effusions (58%) were developed in the pleural cavity ( Fig. 1) , while the remaining 21 cases (42%) were developed in peritoneal cavity. The malignant effusions had developed in the pleural, 31 cases (75.6%) (Fig. 2) , and peritoneal, 10 cases (24.4%), cavities due to many causes (Table 1) .
For cases of malignant and benign effusions, p53 immunocytochemical staining results are shown in Table 2 and Figs. 3-5. Smears having >5% positively stained nuclei were taken as positive. p53 was significantly more expressed in malignant than benign effusions (p < 0.0001).
The p53 immunocytochemical results were then compared with the clinico-cytological diagnosis of the corresponding cases. The results are presented in Table 3 .
p53 had 75.6% sensitivity, 94% specificity, 91.2% positive predictive value (PPV), and 82.5% negative predictive value (NPV) ( Table 6 ).
The proliferation marker ki67 immunostaining was used to determine the labeling index. For the studied malignant and benign effusions, the ki67 labeling index is shown in Table 4 and Figs. 6-8. When using moderate to high labeling index (P10%) as the cutoff point to be considered as positive, the labeling index was significantly higher in malignant effusions compared with benign effusions (p < 0.001). The ki67 immunocytochemical results were then compared with the clinico-cytological diagnosis of the corresponding cases. The results are presented in Table 5 .
ki67 had 73.2% sensitivity, 66% specificity, 63.8% positive predictive value (PPV), and 75% negative predictive value (NPV) ( Table 6) .
Cases were analyzed for combined immunoprofile of p53 and ki67 ( Table 7) . When this comparative analysis was correlated with the clinic-cytological diagnosis, the results are presented in Table 8 .
From these results, when the studied cases revealed positive immunostaining reaction for both markers used, there was 91.2% probability for malignancy. On the other hand, when the studied cases did not express any immunostaining reaction for the two markers used, 94.1% probability to be benign was detected. When the studied cases expressed one marker only, the probability of being benign or malignant was nearly equal (48.5% and 51.5%, respectively).
Discussion
Several studies have suggested that p53 immunostaining does not occur in benign mesothelium but is common in malignancies involving serous effusions [7, 16, 17] . In an attempt to differentiate malignant from benign effusions, p53 immunocytochemical stain had been advocated as a malignant marker in 91 pleural and peritoneal serous effusions. p53 was significantly more expressed in malignant than benign effusions (p < 0.0001). p53 positivity rate was found in 31 of 41 (75.6%) malignant effusions (true positive) and in only 3 of 50 (6%) benign effusions (false positive). Our findings are in close comparison with the experience of Hall et al. [18] who reported that 71% of their studied cytomorphologically malignant cases were p53 positive and none of the non-malignant effusions showed p53 positivity. Akhtar et al. [19] reported 62% positivity rate in malignant effusions while no positivity was recorded in benign cases. Our positivity rate was much higher than that reported by Mayall et al. [16] who reported that the positivity rate of p53 was found in 17 of 35 (48.6%) malignant effusions but was not found in any of 115 benign effusions. Nearly the same results were concluded by Hasteh et al. [20] and Cagle et al. [21] who showed 46.7% and 48% positivity rate in malignant effusions, respectively, and 2.2% and 0% positivity rate in benign cases, respectively. The higher positivity rate in the present study, compared to these studies, may be attributed to the difference in the antibodies used where clone DO-1 MoAb had been used in the current study. VPp958 MoAb was used by Hasteh et al. [20] , clone BP53-12 MoAb was used by Cagle et al. [21] and Do-7 MoAb was used by Mayall et al. [16] . Also in Hasteh et al. study [20] , all malignant cases had mesothelioma and in Cagle et al. [21] , 69% of their studied malignant cases had mesothelioma, while in the present study only two cases had malignant mesothelioma. Mayall et al. [22] reported that malignant mesothelioma had low incidence of p53 mutation. The difference in positivity rate may be also attributed to the fact that there is no generalized accepted standard percentage to define the positivity for p53. The authors applied cutoff level >10% positive nuclei to be positive test. In the current study smears having >5% positive nuclei were considered positive [16, 20] . Stoetzer et al. [23] investigated four different monoclonal antibodies against p53 for the diagnosis of malignancy in effusions. They reported that the used antibodies reacted with 52-75% of malignant effusions but also with 38-80% of benign effusions. They concluded that the sensitivity and specificity of p53 staining in effusions depend strongly on the antibody used. They finally concluded that p53 staining did not improve the identification of malignant cells in serous effusions. The same conclusion was reached by Walts et al. [7] who reported p53 reactivity in 78% of malignant effusion, but they also reported that the benign mesothelial cells in 14% of the studied malignant effusions were also stained positively for p53. In addition, p53 was positive in 73% of their studied benign effusions. They finally concluded that p53 overexpression was not necessarily indicative of malignancy.
Mullick et al. [24] demonstrated p53 positivity in only 41 of 75 (55%) malignant effusions, in 1 of 9 (11%) benign cases, and in 3 of 19 suspicious cases. This positive benign case was subsequently diagnosed as malignant mesothelioma on pleural biopsy, while 2 of the 3 positive suspicious cases showed nonsmall cell lung carcinoma and poorly differentiated large cell carcinoma. They concluded that positive staining in benign and suspicious cells warrants further diagnostic evaluation of the patients and negative p53 protein immunostaining does not exclude malignancy. In the current work, we failed to prove malignancy in the 3 (6%) positively stained benign cases. One case lost follow up examination at the institute after taping, while the other two cases showed no malignancy on follow up after reviewing of their hospital records.
Compared to our study, Pindzola et al. [25] investigated the utility of p53 immunostaining to distinguish reactive mesothelial cells from metastatic malignant ovarian carcinoma in serous effusions. They estimated both the intensity and the percentage of positive nuclear staining. They concluded that the staining intensity should be considered as a critical parameter in this separation, moderate and strong staining intensity were considered truly positive. The percentage of nuclear staining, in their study, was less reliable parameter as 25% of benign cases were positive by this assessment.
In the current work, 3 of 50 benign cases (6%) were positive for p53 (false positive). The percentage of p53 positive cells in studied benign cases (10-20%) was far lower than that seen in malignant cases (45-90%). Although p53 aberrant accumulation is usually detected in malignant tumors, it is also detected in benign lesions characterized by hyperproliferation and hyperplasia. Increased cell proliferation induced wild-type p53 protein synthesis, which could regulate cell proliferation, down regulate bcl-2, and activate apoptotic pathway [19] . King et al. [26] mentioned that occasional overexpression of wildtype p53 protein might be detected immunocytochemically in benign lesions as a result of normal physiological DNA repair in response to hyperproliferation or DNA damaging agents causing false positive results. Levine et al. [27] attributed the cause of p53 positivity in benign lesions to the type of the monoclonal antibodies used as some antibodies could detect both the wild-and mutant-type p53 proteins.
In the current work, there were 10 malignant cases (24.4%) that failed to express p53 positivity (false negative cases). The cause of false negative results could be related to technical factors that reduced or masked the p53 expression in malignant tumors. These factors include methods of cell preparation (smear versus cell block), methods of immunostaining (unstained or destained smears), interpretation subjectivity, and the sensitivity of MoAb used [20] .
In the present study, the sensitivity, specificity, PPV, and NPV of p53 immunocytochemical stain were 75.6%, 94%, 91.2%, and 82.5%, respectively. Our results are comparable to those of Kafiri et al. [10] who reported 70% sensitivity, 100% specificity, 100% PPV, and 77% NPV. Some previous studies had reported moderate sensitivity with high specificity for p53 markers. Akhtar et al. [19] in their similar effort reported sensitivity, specificity, PPV, and NPV of 64%, Table 8 Relation between clinico-cytological diagnosis and expression of p53 and ki67 markers in malignant and benign effusions.
Clinico-cytological diagnosis +ve for both Àve for both +ve for p53 +ve for ki67 Malignant effusion  22  2  9  8  Benign effusion  2  32  1  15   Total  24  34  10  23 100%, 100%, and 72.4%, respectively. Sundblad et al. [28] reported 59% sensitivity and 100% specificity. Other previous works had reported relatively lower sensitivity with high specificity for p53 stain. Hasteh et al. [20] reported 47% sensitivity and 98% specificity. Nearly similar results were reported by Mayall et al. [16] who reported 48.6% sensitivity, 100% specificity, 100% PPV, and 86.5% NPV. The diagnostic value of ki67 immunostaining in human tumors [29, 30] as well as in benign and malignant mesothelial proliferation [31] had been widely documented and accepted.
In the present study, there was significant difference in ki67 expression between malignant and benign effusions (p < 0.001) when using >10% labeling index as cutoff point. This is in accordance with the experience of Scho¨nherr et al. [32] who reported a higher ki67 labeling index in malignant than benign effusions.
However, our data showed that ki67 is not completely reliable to differentiate benign from malignant effusions because 17 of 50 benign cases (34%) were positive (false positive cases) and 11 of 41 malignant cases (26.8%) had <10% labeling index (false negative cases). The expression of proliferative cell markers including ki67 in benign cases was explained by the possible autocrine or paracrine growth factors that upregulated the ki67 gene expression and hence increased the proliferative indices [33] . This explanation was proved by the demonstration of ki67 overexpression in normal breast and pancreatic exocrine cells in other studies [34, 35] . Hasteh et al. [20] concluded that the cause of high labeling index in their benign cases might be due to the presence of lymphocytes in the effusions which were frequently positive and could cause difficulty in estimation of labeling index by immunostaining. In our study some benign cases contained inflammatory cells, including lymphocytes, in the background. ki67 interpretation was estimated among the total epithelioid cells counted only, not inflammatory cells.
On the other hand, Saleh et al. [33] attributed the cause of low labeling index in some malignant cases to the down-regulation of ki67 gene by the effect of some autocrine and paracrine uncertain factors. Sikora et al. [36] also attributed the cause of the false negative cases to the low proliferative and turnover activity in certain tumors or to technical factors that cause reduction or masking of ki67 expression. These factors included using destained slides for immunostaining that lead to loss of some antigenicity by the destaining procedure. Kimura et al. [37] concluded that percentages of immunostained cells above and below, but close to, the cutoff point may account for the error in interpretation. They recommended that the assessment of immunocytochemistry should be performed using computer assistance to avoid wrong interpretations. Other authors attributed the cause of the false negative cases to the low cellularity of the metastatic epithelial cells in the effusions [20] .
In the present study, the sensitivity, specificity, PPV, and NPV of ki67 immunocytochemical stain were 73.2%, 66%, 63.8%, and 75%, respectively. Our results are lower than those reported by Taheri et al. [38] who demonstrated 88% sensitivity and 94% specificity. Taheri et al. [31] in another work evaluated the diagnostic value of ki67 and repp86 in differentiation of benign mesothelial proliferation from malignancy and reported 88% sensitivity and 92% specificity for ki67. Cakir et al. [9] evaluated telomerase activity and ki67 immunostaining to differentiate malignant from mesothelial proliferation and reported 74% sensitivity and 86% specificity for ki67. Kimura et al. [37] studied three proliferative markers (MCM7, Topo IIa, and ki67) to differentiate malignant from mesothelial proliferation and reported 64.3% sensitivity and 92.9% specificity for ki67 using 30% labeling index as cutoff point. Scho¨nherr et al. [32] in their similar study on pleural cytology showed 77.8% sensitivity and 90.9% specificity for ki67 when using a cutoff point of >10%, but when they assumed a cutoff point of 25% as positive test, specificity became 100% but sensitivity was 25%. The improvement of specificity with lowering of sensitivity when increasing the cutoff point was also reported by Hasteh et al. [20] who estimated 57% sensitivity and 56% specificity for ki67 when using >10% as cutoff point. They reported 16% sensitivity and 91% specificity after using high labeling index (>40%) as positive test.
In the present study, when assuming >25% labeling index as cutoff point for positivity; all benign cases were correctly diagnosed and only 25 of 41 malignant cases (61%) were true positive. Thus the newly estimated sensitivity and specificity were 61% and 100%, respectively. Like others, we found that increasing the cutoff level could diagnose all benign cases but miss more malignant cases resulting in increasing specificity and decreasing sensitivity.
Hasteh et al. [20] concluded that each immunostaining marker has its own sensitivity and specificity when used alone. No single antibody has been shown to be 100% sensitive and absolutely specific for identification of malignant cells in serous effusions. They advised to use a panel of immunocytochemical stains to make this distinction in cytological effusions. Consistent with the role of p53 in controlling cellular proliferation, it was hypothesized that there was an association between p53 positivity and the number of ki67 positive cells in different neoplasms, suggesting that aberrant p53 expression is enhanced by cellular proliferation [23] . To verify whether the simultaneous association of p53 and ki67 immunodetection could help in differentiating malignant from benign effusions with a high reliability, the comparative expression of both markers was estimated and correlated with clinico-cytological diagnosis. In the current work, it was important to recognize that only 24 of the 91 studied cases (26.4%) coexpressed both markers. It was found that for both p53 and ki67 positive cases, 91.7% were malignant. For cases that were both p53 and ki67 negative, 94% were benign. For cases that were p53 positive and ki67 negative, 90% were malignant. For cases that were p53 negative and ki67 positive, 65.2% were benign. p53 was considered as a more reliable malignant marker than ki67. For cases that expressed ki67 only, they should be interpreted cytomorphologically in correlation with clinical and radiological findings.
Conclusion
Benign and malignant effusions showed significantly different staining pattern for p53 and ki67. When used individually, p53 immunostaining can truly diagnose 75.6% and 94% of the malignant and benign cases, respectively. ki67 immunostaining can correctly identify 73.2% and 66% of the malignant and benign cases, respectively. When used in combination, 91.7% of p53 and ki67 positive cases were malignant while 94% of p53 and ki67 negative cases were benign. Hence they could be used when the cytomorphology fails to provide a definitive diagnosis.
